Soleno Hit With Securities Class Action Over Prader‑Willi Drug DCCR

Overview

• Investor‑rights firms, in Thursday and Friday notices, urged Soleno shareholders to act before May 5, 2026 to seek lead‑plaintiff status.
• The suit, filed in the Northern District of California, covers purchases from March 26, 2025 through November 4, 2025.
• Plaintiffs allege Soleno downplayed Phase 3 safety issues such as excess fluid retention and overstated DCCR’s commercial prospects.
• The timeline cited includes Scorpion Capital’s August 15, 2025 report, a September 10 filing disclosing a patient death after DCCR, and a November 4 update that launches saw fewer start forms and more discontinuations.
• Soleno’s shares fell about 26% on November 5, 2025 after the launch update, and firms including Hagens Berman, Rosen, Kessler Topaz, Glancy Prongay, and Faruqi are now soliciting whistleblowers and affected investors.